

Abstract

- The aim of this presentation is to review recent evidence-based studies pertaining to anti-thrombotic management in atrial fibrillation (AF) patients requiring percutaneous coronary intervention (PCI). Highlights will include recent updates from the 2018 Canadian Cardiovascular Society (CCS) anti-platelet guidelines pertaining to management of AF and elective PCI without high-risk features and AF with PCI in acute coronary syndromes (ACS) or elective high-risk PCI.